TABLE 4.
Stratified analysis of outcomes of patients in the empirical- and targeted-therapy cohorts treated with β-lactam/β-lactam inhibitor combinations or carbapenems, according to quartiles of the propensity score
| Cohort, PS quartile | No. of patients with indicated outcome/no. of patients that received indicated treatment (%) |
|||||
|---|---|---|---|---|---|---|
| Cure/improvement |
Mortality |
|||||
| BLBIs | Carbapenems | P value | BLBIs | Carbapenems | P value | |
| Empirical therapy | ||||||
| n = 170 | n = 195 | n = 170 | n = 195 | |||
| 1st | 7/12 (58.3) | 59/76 (77.6) | 0.15 | 4/12 (33.3) | 18/76 (23.7) | 0.47 |
| 2nd | 29/35 (82.9) | 51/59 (86.4) | 0.76 | 5/35 (14.3) | 6/59 (10.1) | 0.78 |
| 3rd | 38/50 (76.0) | 31/41 (75.6) | 0.96 | 9/50 (18.0) | 10/41 (24.4) | 0.62 |
| 4th | 62/73 (84.9) | 13/19 (68.4) | 0.10 | 12/73 (16.4) | 5/19 (26.3) | 0.32 |
| Targeted therapy | ||||||
| n = 92 | n = 509 | n = 92 | n = 509 | |||
| 1st | 0 | 127/150 (84.7) | 0 | 21/150 (14.0) | ||
| 2nd | 2/3 (66.7) | 128/147 (87.1) | 0.30 | 1/3 (33.3) | 19/147 (12.9) | 0.30 |
| 3rd | 13/13 (100.0) | 115/137 (83.9) | 0.12 | 0/13 (0.0) | 21/137 (15.3) | 0.13 |
| 4th | 68/76 (89.5) | 65/75 (86.7) | 0.77 | 8/76 (10.5) | 10/75 (13.3) | 0.62 |